ZURICH, March 3 (Reuters) - Novartis AG (NOVN.VX: Quote, Profile, Research) has submitted its two-in-one Exforge blood pressure-lowering drug for approval in the European Union, the Swiss drug maker said on Friday.
"In addition to the European Union, Exforge is on schedule to be submitted in 2006 for approval in the United States as well as in other countries," Novartis said in a statement. Exforge is a once-daily tablet that combines two blood-pressure treatments -- Novartis's valsartan, which it markets under the name of Diovan, and amlodipine, which Pfizer Inc. (PFE.N: Quote, Profile, Research) markets as Norvasc.
